Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 146

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 146
---
 discount
received by it because the underwriter has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering
transactions.

These stabilizing
transactions, short sales, purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering
transactions may have the effect of raising or maintaining the market price of our Depositary Shares or preventing or retarding a decline
in the market price of our Depositary Shares. As a result of these activities, the price of our Depositary Shares may be higher than the
price that otherwise might exist in the open market. The underwriter may carry out these transactions on the NASDAQ Capital Market, in
the over-the-counter market or otherwise. Neither we nor the underwriter make any representation or prediction as to the effect that the
transactions described above may have on the price of the shares and warrants. Neither we, nor the underwriter make any representation
that the underwriter will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued
without notice.

Other Relationships and Affiliations

The underwriter
and its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage
activities. The underwriter and its affiliates may from time to time in the future engage with us and perform services for us or in the
ordinary course of their business for which they will receive customary fees and expenses. In the ordinary course of their various business
activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers, and such investment and securities activities may involve securities and/or instruments of us. The underwriter and its respective
affiliates may also make investment recommendations and/or publish or express independent research views in respect of these securities
or instruments and may at any time hold, or recommend to clients that it acquires, long and/or short positions in these securities and
instruments.

| 79 |

Selling Restrictions

Canada.
The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions (NI 45-106), and in Ontario,